Perspectum Diagnostics was founded by physicians, scientists, and engineers with patented technology and know-how to develop solutions for major unmet needs in diagnostic medicine. We focus on detection and accurate, quantitative characterisation of disease using MRI of the liver, gallbladder and pancreas. Our flagship product, LiverMultiScan™, is FDA 510(k) cleared and CE-marked for clinical use, and delivered via our ISO-27001 compliant cloud-based quantitative analysis service. We are involved in a large number of clinical trials and collaborations to develop and explore the utility of our technology for new clinical indications. This includes running Europe’s largest Non-Alcoholic Fatty Liver Disease study (RADiCAL), processing liver imaging data for 100,000 subjects as part of the UK Biobank, in addition to multiple clinical trials with pharmaceutical and biotechnology companies.